Verition Fund Management
CRDL

Verition Fund Management’s Cardiol Therapeutics CRDL Stock Holding History

Verition Fund Management’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,109
Closed -$22.4K – 3242
2024
Q2 		$22.4K Buy
+11,109
New +$23.6K ﹤0.01% 2859
2022
Q1 		– Sell
-457,732
Closed -$847K – 2773
2021
Q4 		$847K Buy
+457,732
New +$1.26M 0.01% 1399

Other funds holding CRDL

TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
LSA
Lion Street Advisors Austin, Texas $289M AUM 3.13% 1-Year Est. Return
FIA
Foundations Investment Advisors Phoenix, Arizona $8.07B AUM 24.97% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
MOS
MGO One Seven Beachwood, Ohio $4.98B AUM 22.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Verition Fund Management's CRDL Position: Q3 2024 in Review

Verition Fund Management sold out of Cardiol Therapeutics (CRDL) in Q3 2024, closing a stake of 11,109 shares — an estimated $22.4K sold.

Verition Fund Management first reported a position in CRDL in Q4 2021 and held it in 2 quarters. The position peaked at $847K in Q4 2021. 41 funds tracked by Wall St. Rank hold CRDL as of Q3 2024.

  • Verition Fund Management reported no remaining Cardiol Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Verition Fund Management sold 11,109 Cardiol Therapeutics shares in Q3 2024, an estimated $22.4K.
  • Verition Fund Management first reported a position in Cardiol Therapeutics in Q4 2021 and held it in 2 quarters.
  • Verition Fund Management's Cardiol Therapeutics position peaked at $847K in Q4 2021.
  • 41 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q3 2024.

Based on Verition Fund Management's 13F filing for Q3 2024, filed 14 Nov 2024.